Back to top
more

Solid Biosciences (SLDB)

(Real Time Quote from BATS)

$5.98 USD

5.98
244,394

-0.07 (-1.16%)

Updated Oct 11, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Techne (TECH) Lags Q1 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of -3.78% and 4.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for

Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline

Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Novartis (NVS) This Earnings Season?

Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.

Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.76% and 77.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates

Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?

Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.

Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision

The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the delay

Merck's (MRK) Pneumococcal Vaccine sBLA Faces FDA Delay

Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Solid Biosciences Inc. (SLDB) Reports Q4 Loss, Lags Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15% and 9.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy

Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.79% and 7.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy

Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.

Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Kinjel Shah headshot

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 5.56% and 14.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

Radhika Saraogi headshot

Should You Buy Solid Biosciences (SLDB) Ahead of Earnings?

Solid Biosciences (SLDB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CuriosityStream (CURI) to Post Q4 Earnings: What's in Store?

CuriosityStream's (CURI) fourth-quarter 2020 results are expected to reflect expanding subscriber base, driven by strong factual content portfolio.

Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down

Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.

Sarepta (SRPT) Inks New Gene Editing Research Collaboration

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.